NEWS: 公告在东京证券交易所JASDAQ标准市场新上市

表纸
市场调查报告书

感染疾病疫苗市场业务联盟:契约条件、协定内容

Global Infectious Vaccines Partnering Terms and Agreements 2014 to 2020: Deal trends, players and financials

出版商 Current Partnering, a division of Wildwood Ventures Limited 商品编码 253943
出版日期 内容资讯 英文 350+ Pages
订单完成后即时交付
价格
感染疾病疫苗市场业务联盟:契约条件、协定内容 Global Infectious Vaccines Partnering Terms and Agreements 2014 to 2020: Deal trends, players and financials
出版日期: 2020年11月01日内容资讯: 英文 350+ Pages
简介

本报告提供感染疾病相关的各种契约--产业联盟(伙伴关系)和其他资本交易联盟--的契约条件的趋势相关分析、近几年各种契约趋势、大规模契约及大型制药企业的契约概要、契约的种类、开发阶段、疾病区分、各技术区分名录等汇整资料,为您概述为以下内容。

摘要整理

第1章 简介

第2章 感染疾病疫苗相关的资本交易趋势

  • 概要
  • 趋势感染疾病疫苗相关的产业联盟:过去数年
  • 大型制药企业的感染疾病疫苗相关的资本交易行动
  • 积极对感染疾病疫苗相关的资本交易行动的制药企业
  • 感染疾病疫苗相关的资本交易:各交易类型
  • 感染疾病疫苗相关的资本交易:各开发阶段
  • 感染疾病疫苗相关的资本交易:各适应症
  • 感染疾病疫苗相关的资本交易:疫苗/补助剂
  • 伙伴关系相关公开的交易条件
  • 感染疾病疫苗相关的资本交易结构、案例

第3章 代表性的资本交易

  • 简介
  • 代表性资本交易(交易额顺序的排行榜)

第4章 大型制药企业的感染疾病疫苗相关的资本交易

  • 简介
  • 关于资料的有效利用方法
  • 大型制药企业的感染疾病疫苗相关资本交易:企业简介
    • Abbott
    • Astellas Pharma Inc.
    • 第一三共
    • Gilead Sciences
    • GlaxoSmithKline
    • Johnson & Johnson
    • Merck & Co
    • Novartis
    • Pfizer
    • Purdue
    • Sanofi
    • 武田药品工业

第5章 大型生物工学企业的感染疫苗相关的资本交易

第6章 感染疾病疫苗的资本交易企业一览

  • 简介
  • 相关企业、团体名(ABC顺序)
  • 临床实验的各阶段
  • 各交易类型
    • 资产收购
    • 资产转让
    • 大型制药企业的授权合约(outlicensing)
    • 共同开发
    • 共同研究开发(R&D)
    • 共同市场
    • 契约服务
    • 共同促销
    • 共同研究开发契约(CRADA)
    • 交叉许可
    • 开发
    • 流通
    • 股票购买
    • 评估
    • 给予
    • 合资企业
    • 授权合约
    • 诉讼
    • 制造
    • OEM
    • 行销
    • 资材迁移
    • 选择
    • 推销
    • 调查
    • 权利金、财政
    • 调停
    • 衍生公司
    • 辅助许可证
    • 供给
    • 技术转移
    • 终结
    • 补偿
  • 感染疾病的治疗领域
  • 相关各技术

第7章 联盟资源中心

  • 线上、伙伴关系
  • 合作伙伴活动
  • 相关资料

附录

图表一览

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: CP22061

The Global Infectious Vaccines Partnering Terms and Agreements 2014 to 2020: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the infectious vaccines partnering deals and agreements entered into by the worlds leading healthcare companies

The Global Infectious Vaccines Partnering Terms and Agreements 2014 to 2020: Deal trends, players and financials report provides a detailed understanding and analysis of how and why companies enter infectious vaccines partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

This report provides details of the latest infectious vaccines agreements announced in the healthcare sectors.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all infectious vaccines partnering deals announced since January 2014, including financial terms where available, including over 550 links to online deal records of actual infectious vaccines partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of Infectious Vaccines dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Infectious Vaccines dealmaking since 2014, including details of average headline, upfront, milestone and royalty terms. Infectious Vaccines deals since 2014. Deals are listed by headline value, signed by big pharma, most active Infectious Vaccines dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 3 provides a review of the leading Infectious Vaccines deals since 2014. Deals are listed by headline value, signed by big pharma, most active Infectious Vaccines dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Infectious Vaccines dealmaking with a brief summary followed by a comprehensive listing of Infectious Vaccines deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Infectious Vaccines partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Infectious Vaccines partnering deals signed and announced since Jan 2014. The chapter is organized by specific Infectious Vaccines technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Infectious Vaccines partnering company A-Z, deal type definitions and Infectious Vaccines partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in Infectious Vaccines partnering and dealmaking since Jan 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Infectious Vaccines technologies and products.

Report scope

Global Infectious Vaccines Partnering Terms and Agreements 2014 to 2020: Deal trends, players and financials is intended to provide the reader with an in-depth understanding and access to infectious vaccines trends and structure of deals entered into by leading companies worldwide.Global Infectious Vaccines Partnering Terms and Agreements 2014 to 2020: Deal trends, players and financials includes:

  • Trends in infectious vaccines dealmaking in the biopharma industry since 2014
  • Analysis of infectious vaccines deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to over 550 infectious vaccines deal records
  • Identify the most active infectious vaccine dealmakers since 2014
  • The leading infectious vaccines deals by value since 2014
  • Includes adjuvant deals and alliances since 2014

In Global Infectious Vaccines Partnering Terms and Agreements 2014 to 2020: Deal trends, players and financials, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific infectious therapy target
  • Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Infectious Vaccines Partnering Terms and Agreements 2014 to 2020: Deal trends, players and financials report provides comprehensive access to available deals and contract documents for over 550 infectious vaccines deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Global Infectious Vaccines Partnering Terms and Agreements provides the reader with the following key benefits:

  • In-depth understanding of infectious vaccines deal trends since 2014
  • Access infectious vaccines deal headline, upfront, milestone and royalty data
  • Analysis of the structure of infectious vaccines agreements with numerous real life case studies
  • Comprehensive access to over 550 links to actual infectious vaccines deals entered into by the world's biopharma companies, together with real world clause examples
  • Identify leading infectious vaccines deals by value since 2014
  • Identify the most active infectious vaccines dealmakers since 2014
  • Insight into the terms included in infectious vaccines agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Infectious Vaccines dealmaking

  • 2.1. Introduction
  • 2.2. Infectious Vaccines partnering over the years
  • 2.3. Most active Infectious Vaccines dealmakers
  • 2.4. Infectious Vaccines partnering by deal type
  • 2.5. Infectious Vaccines partnering by therapy area
  • 2.6. Deal terms for Infectious Vaccines partnering
    • 2.6.1 Infectious Vaccines partnering headline values
    • 2.6.2 Infectious Vaccines deal upfront payments
    • 2.6.3 Infectious Vaccines deal milestone payments
    • 2.6.4 Infectious Vaccines royalty rates

Chapter 3 - Leading Infectious Vaccines deals

  • 3.1. Introduction
  • 3.2. Top Infectious Vaccines deals by value

Chapter 4 - Most active Infectious Vaccines dealmakers

  • 4.1. Introduction
  • 4.2. Most active Infectious Vaccines dealmakers
  • 4.3. Most active Infectious Vaccines partnering company profiles

Chapter 5 - Infectious Vaccines contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Infectious Vaccines contracts dealmaking directory

Chapter 6 - Infectious Vaccines dealmaking by technology type

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

Appendices

  • Appendix 1 - Infectious Vaccines deals by company A-Z
  • Appendix 2 - Infectious Vaccines deals by stage of development
  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Regulatory
  • Marketed
  • Formulation
  • Appendix 3 - Infectious Vaccines deals by deal type
  • Asset purchase
  • Assignment
  • Bigpharma outlicensing
  • Co-development
  • Collaborative R&D
  • Co-market
  • Co-promotion
  • CRADA
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Manufacturing
  • Marketing
  • Option
  • Promotion
  • Research
  • Settlement
  • Spin out
  • Sub-license
  • Supply
  • Technology transfer
  • Termination
  • Appendix 4 - Infectious Vaccines deals by therapy area
  • Appendix 5 - Deal type definitions
  • About Wildwood Ventures
  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering
  • Table of figures
  • Figure 1: Infectious Vaccines partnering since 2014
  • Figure 2: Active Infectious Vaccines dealmaking activity since 2014
  • Figure 3: Infectious Vaccines partnering by deal type since 2014
  • Figure 4: Infectious Vaccines partnering by disease type since 2014
  • Figure 5: Infectious Vaccines deals with a headline value
  • Figure 6: Infectious Vaccines deals with an upfront value
  • Figure 7: Infectious Vaccines deals with a milestone value
  • Figure 8: Infectious Vaccines deals with a royalty rate value
  • Figure 9: Top Infectious Vaccines deals by value since 2014
  • Figure 10: Most active Infectious Vaccines dealmakers since 2014
  • Figure 11: Online partnering resources
  • Figure 12: Forthcoming partnering events